Description
Sorafenib (Bay 43-9006) is a multikinase inhibitor that targets Raf-1, B-Raf, VEGFR2, VEGFR3, VEGFR4, PDGFRβ, FLT3, c-Kit, and others (IC50=6/22/90/15/20/20/57/58 nM) with oral activity. It exhibits antitumor properties and can induce autophagy, apoptosis, and agonistic iron death.
Solubility Information
H2O: < 1 mg/mL (insoluble or slightly soluble)10% DMSO+40% PEG300+5% Tween 80+45% Saline: 5.9 mg/mL (12.69 mM), In vivo: Suspension. Please add co-solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately.DMF: 3.33 mg/mL (7.17 mM)DMSO: 55 mg/mL (118.33 mM)Ethanol: < 1 mg/mL (insoluble or slightly soluble)